After years of weight issues and related health problems, Walter decided it was time to make a change. With the help of Dr. Kuldeep Singh of the Maryland Bariatric Center, Walter is now living his life to the fullest.

A determined Atlanta resident travels 700 miles to Mercy, seeking the expertise of Dr. Clifford Jeng for a complex medical issue.

Hear the inspiring story of a man who survived colon cancer, liver cancer and a liver transplant - treated by a team doctors at Mercy.

Yolanda, a hard-working entrepreneur, tackles two separate health issues with the assistance of Mercy surgeons.

Topic of Study: Breast Cancer This is a randomized, open-label, Phase 3 study of Sacituzumab Govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with Anti-PD-(L)1 Agents in the early setting whose tumors do express PD-L1. (Clinicaltrials.gov ID#: NCT05382299)

Topic of Study: Breast Cancer This is a randomized Phase III trial comparing active symptom monitoring plus patient education versus patient education alone to improve persistence with endocrine therapy in young women with Stage I-III breast cancer (Aspen). (Clinicaltrials.gov ID#: NCT05568472)

Topic of Study: Breast Cancer This is a Phase Ib/III, open-label, randomised study of Capivasertib plus CDK4/6 inhibitors and Fulvestrant versus CDK4/6 inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative locally advanced, unresectable or metastatic breast cancer. (Clinicaltrials.gov ID#: NCT04862663)

Topic of Study: Breast Cancer This is a study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in participants with previously untreated, PD-L1-Positive, locally-advanced unresectable or metastatic Triple-Negative breast cancer. (Clinicaltrials.gov ID#: NCT05852691)

Topic of Study: Inflammatory Bowel Disease The goals of this prospective cohort study are to study the natural history of IBD, prevalence and incidence of comorbidities, and targeted adverse events, as well as utilization patterns and comparative effectiveness and safety of approved IBD treatments. (Clinicaltrials.gov ID#: NCT03162549).